Assessment of Serum Cystatin C and Apolipoprotein Levels in Chronic Kidney Disease Patients
DOI:
https://doi.org/10.51173/ijmhs.v1i1.5Keywords:
CKD, GFR , Apo A , Apo B , Cystatin CAbstract
Background: Chronic Kidney Disease (CKD) is the presence of kidney dysfunctions less than sixty (ml/min) of the estimated glomerular filtration rate (eGFR) per 1.73 square meters that has prolonged for at least three months; it is widespread and affects over 10% of individuals worldwide.
Objective of Study: The objective of this study was to assess how well the kidney function indicators cystatin C, apolipoprotein A, and apolipoprotein B functioned in people with CKD.
Materials and Methods: In this study cystatin C, apolipoprotein A, apolipoprotein B, creatinine, urea, and uric acid levels were determined. A total of 150 samples of blood, which were gathered from one hundred patients who had chronic kidney disease aged between 20 and 69 years and fifty healthy subjects as controls aged between 23 and 67 years, at the medical City-Baghdad hospital/Iraq during the period from December 2022 to April 2023. Cystatin C, apolipoprotein A, and apolipoprotein B were evaluated by using an enzymatic linked absorption assay (Sandwich Elisa), and the assessments of urea, creatinine, and uric acid were accomplished with apparatus Cobas c111.
Results: Patients with chronic kidney disease had highly significantly raised levels of cystatin C, apolipoprotein B levels, serum creatinine, urea, and uric acid in comparison with the control group (P-value = 0.000). In contrast, the apolipoprotein A levels in the patient groups were considerably lower than in the control group (P-value = 0.000).
Conclusion: In conclusion, cystatin C and apolipoprotein B levels were elevated with kidney dysfunction, while a reduction of apolipoprotein A levels may be used as an indicator of probable risk for individuals with chronic kidney disease (CKD).
References
Murton, M., Goff-Leggett, D., Bobrowska, A., Garcia Sanchez, J. J., James, G., Wittbrodt, E., & Tuttle, K. (2021). Burden of chronic kidney disease by KDIGO categories of glomerular filtration rate and albuminuria: a systematic review. Advances in therapy, 38, 180-200. https://doi.org/10.1007/s12325-020-01568-8.
Andronovici, A. M., Caruntu, I. D., Onofriescu, M., Hurjui, L. L., Giusca, S. E., Covic, A. S., & Foia, L. G. (2022). TNF-α, IL-1β, MMP-8 Crevicular profile in patients with chronic kidney disease and periodontitis. Applied Sciences, 12(2), 736. https://doi.org/10.3390/app12020736.
Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021). Chronic kidney disease. The lancet, 398(10302), 786-802. DOI:10.1016/s0140-6736(21)00519-5.
Sabri, N. W., Rashid, B. A., Shwiehk, R. S., & Mahdy, A. H. (2023). Assessment of Risk Factors of Chronic Kidney Disease among Patients Attending Medical City Complex. Journal of Techniques, 5(2), 147-154. DOI: https://doi.org/10.51173/jt.v5i2.885.
Lees, J. S., Welsh, C. E., Celis-Morales, C. A., Mackay, D., Lewsey, J., Gray, S. R., & Mark, P. B. (2019). Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. Nature medicine, 25(11), 1753-1760. DOI : https://doi.org/10.1038/s41591-019-0627-8.
Hayn, M., Blötz, A., Rodríguez, A., Vidal, S., Preising, N., Ständker, L., & Kirchhoff, F. (2021). Natural cystatin C fragments inhibit GPR15-mediated HIV and SIV infection without interfering with GPR15L signaling. Proceedings of the National Academy of Sciences, 118(3), e2023776118. https://doi.org/10.1073/pnas.2023776118.
Linne, E., Elfström, A., Åkesson, A., Fisher, J., Grubb, A., Pettilä, V., & Bentzer, P. (2022). Cystatin C and derived measures of renal function as risk factors for mortality and acute kidney injury in sepsis–a post-hoc analysis of the FINNAKI cohort. Journal of Critical Care, 72, 154148. https://doi.org/10.1016/j.jcrc.2022.154148.
Zadeh, H. (2021). The Genealogy of Racialized Method: eGFR as Case Study.
Torres-Romero, J. C., Lara-Riegos, J. C., Parra, E. A. E., Sánchez, V. F., Arana-Argáez, V. E., Uc-Colli, S., & Alvarez-Sánchez, M. E. (2020). Lipoproteomics: Methodologies and Analysis of Lipoprotein-Associated Proteins along with the Drug Intervention. In Drug Design-Novel Advances in the Omics Field and Applications. IntechOpen. DOI: http://dx.doi.org/10.5772/intechopen.93634.
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B. (2021). Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. Metabolites, 11(10), 690. https://doi.org/10.3390/
metabo11100690.
Xu, X., Song, Z., Mao, B., & Xu, G. (2022). Apolipoprotein A1‐related proteins and reverse cholesterol transport in antiatherosclerosis therapy: Recent progress and future perspectives. Cardiovascular Therapeutics, 2022(1), 4610834. https://doi.org/10.1155/2022/4610834.
Vlad, C. E., Foia, L., Popescu, R., Ivanov, I., Luca, M. C., Delianu, C., ... & Florea, L. (2019). Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End‐Stage Renal Disease. Journal of diabetes research, 2019(1), 6906278. https://doi.org/10.1155/2019/6906278.
Shepard, B. D. (2019). Sex differences in diabetes and kidney disease: mechanisms and consequences. American Journal of Physiology-Renal Physiology, 317(2), F456-F462. https://doi.org/10.1152/ajprenal.00249.2019.
M. Provenzano, M., Rotundo, S., Chiodini, P., Gagliardi, I., Michael, A., Angotti, E., & Andreucci, M. (2020). Contribution of predictive and prognostic biomarkers to clinical research on chronic kidney disease. International Journal of Molecular Sciences, 21(16), 5846. https://doi.org/10.3390/ijms21165846.
Smereczański, N. M., & Brzóska, M. M. (2023). Current levels of environmental exposure to cadmium in industrialized countries as a risk factor for kidney damage in the general population: A comprehensive review of available data. International Journal of Molecular Sciences, 24(9), 8413. https://doi.org/10.3390/ijms24098413.
Fernandez-Prado, R., Perez-Gomez, M. V., & Ortiz, A. (2020). Pelacarsen for lowering lipoprotein (a): implications for patients with chronic kidney disease. Clinical kidney journal, 13(5), 753-757. https://doi.org/10.1093/ckj/sfaa001.
Zhao, W., Li, J., Zhang, X., Zhou, X., Xu, J., Liu, X., & Liu, Z. (2020). Apolipoprotein B and renal function: across-sectional study from the China health and nutrition survey. Lipids in Health and Disease, 19, 1-9. https://doi.org/10.1186/s12944-020-01241-7.
Goek, O. N., Köttgen, A., Hoogeveen, R. C., Ballantyne, C. M., Coresh, J., & Astor, B. C. (2012). Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples. Nephrology Dialysis Transplantation, 27(7), 2839-2847. https://doi.org/10.1093/ndt/gfr795.
Weiss, L., Keaney, J., Szklanna, P. B., Prendiville, T., Uhrig, W., Wynne, K., ... & Maguire, P. B. (2021). Nonvalvular atrial fibrillation patients anticoagulated with rivaroxaban compared with warfarin exhibit reduced circulating extracellular vesicles with attenuated pro‐inflammatory protein signatures. Journal of Thrombosis and Haemostasis, 19(10), 2583-2595. https://doi.org/10.1111/jth.15434.
Yang, W. Y., Wang, J., Li, X. H., Xu, B., Yang, Y. W., Yu, L., ... & Feng, J. F. (2023). Analysis of non-targeted serum metabolomics in patients with chronic kidney disease and hyperuricemia. Biotechnology and Genetic Engineering Reviews, 1-27. https://doi.org/10.1080/02648725.2023.2204715.
Rinde, N. B., Enoksen, I. T., Melsom, T., Fuskevåg, O. M., Eriksen, B. O., & Norvik, J. V. (2023). Nitric oxide precursors and dimethylarginines as risk markers for accelerated measured GFR decline in the general population. Kidney International Reports, 8(4), 818-826. https://doi.org/10.1016/j.ekir.2023.01.015.
Kulvichit, W., Kellum, J. A., & Srisawat, N. (2021). Biomarkers in acute kidney injury. Critical care clinics, 37(2), 385-398. https://www.criticalcare.theclinics.com/article/S0749-0704(20)30117-2/abstract.
Salman, M. N., & Hamzah, A. S. (2022). Determination of Cystatin C Level in a Sample of Patients with Chronic Kidney Disease. Journal of Techniques, 4(Special Issue), 7-11. DOI: https://doi.org/10.51173/jt.v4i33.520.
Zhan, X., Chen, Y., Yan, C., Liu, S., Deng, L., Yang, Y., ... & Chen, Q. (2018). Apolipoprotein B/apolipoprotein A1 ratio and mortality among incident peritoneal dialysis patients. Lipids in Health and Disease, 17, 1-7. https://doi.org/10.1186/s12944-018-0771-z.
Srikantharajah, M., Doshi, R., Banerjee, D., Jha, V., & Annear, N. M. (2023). Investigating Kidney Disease. In Management of Kidney Diseases (pp. 11-33). Cham: Springer International Publishing. https://link.springer.com/chapter/10.1007/978-3-031-09131-5_2.
Henry, B. M., Szergyuk, I., de Oliveira, M. H. S., Abosamak, M. F., Benoit, S. W., Benoit, J. L., & Lippi, G. (2021). Alterations in the lipid profile associate with a dysregulated inflammatory, prothrombotic, anti-fibrinolytic state and development of severe acute kidney injury in coronavirus disease 2019 (COVID-19): A study from Cincinnati, USA. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15(3), 863-868. https://doi.org/10.1016/j.dsx.2021.04.011.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Raghad Hassan Ali, Ahmed Saadi Hassan, Abdulrazzaq Neamah Zghair, Anil Kumar Sharma
This work is licensed under a Creative Commons Attribution 4.0 International License.
